What factors impact your decision to include bevacizumab with primary chemotherapy for patients with BRCA+ or HRD+ ovarian cancer?  

Does your practice vary based on risk status (low vs high risk) or specific mutation status (BRCA+ vs HRD+) given PAOLA subset analyses



Answer from: at Academic Institution

Answer from: at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: at Community Practice